title: [Personalized molecular medicine: new paradigms in the treatment of cochlear implant and cancer patients].
abstract: OBJECTIVE
  To evaluate present options for the indication of cochlear implants (CI) and new forms of treatment for head and neck cancer, melanomas and basal cell carcinomas, with emphasis on future perspectives.
  
  
  METHODS
  A literature search was performed in the PubMed database. Search parameters were "personalized medicine", "individualized medicine" and "molecular medicine".
  
  
  RESULTS
  Personalized medicine based on molecular-genetic evaluation of functional proteins such as otoferlin, connexin 26 and KCNQ4 or the Usher gene is becoming increasingly important for the indication of CI in the context of infant deafness. Determination of HER2/EGFR mutations in the epithelial growth factor receptor (EGFR) gene may be an important prognostic parameter for therapeutic decisions in head and neck cancer patients. In basal cell carcinoma therapy, mutations in the Hedgehog (PCTH1) and Smoothened (SMO) pathways strongly influence the indication of therapeutic Hedgehog inhibition, e.g. using small molecules. Analyses of c-Kit receptor, BRAF-600E and NRAS mutations are required for specific molecular therapy of metastasizing melanomas. The significant advances in the field of specific molecular therapy are best illustrated by the availability of the first gene therapeutic procedures for treatment of RPE65-induced infantile retinal degradation.
  
  
  CONCLUSIONS
  The aim of personalized molecular medicine is to identify patients who will respond particularly positively or negatively (e.g. in terms of adverse side effects) to a therapy using the methods of molecular medicine. This should allow a specific therapy to be successfully applied or preclude its indication in order to avoid serious adverse side effects. This approach serves to stratify patients for adequate treatment.
authors.affiliation: Universitätsklinik für HNO-Heilkunde, Universität Tübingen, Elfriede-Aulhorn-Str. 5, 72076, Tübingen, Deutschland, Hans-Peter.Zenner@med.uni-tuebingen.de.
authors.forename: H P
authors.initials: HP
authors.lastname: Zenner
authors.forename: M
authors.initials: M
authors.lastname: Pfister
authors.forename: N
authors.initials: N
authors.lastname: Friese
authors.forename: E
authors.initials: E
authors.lastname: Zrenner
authors.forename: M
authors.initials: M
authors.lastname: Röcken
mesh_terms: D003054:Cochlear Implants; D005819:Genetic Markers / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000628:therapy*; D034381:Hearing Loss / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D057285:Precision Medicine / Q000379:methods*
chemical_list: D005819:Genetic Markers